14.98
1.45%
-0.22
Handel nachbörslich:
15.04
0.06
+0.40%
Range Cancer Therapeutics ETF Aktie (CNCR) Neueste Nachrichten
(CNCR) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Stock Traders Daily
(CNCR) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Stock Traders Daily
Best ETF Areas of Last Week
Zacks Investment Research
Best ETF Areas of Last Week - Zacks Investment Research
Zacks Investment Research
Best ETF Areas of Last Week - Yahoo Finance
Yahoo Finance
The Zacks Analyst Blog Highlights CRPT, WEED, SMH, CNCR and KBWP
Zacks Investment Research
The Zacks Analyst Blog Highlights CRPT, WEED, SMH, CNCR and KBWP - Yahoo Finance
Yahoo Finance
5 Market-Beating Sector ETFs of Q1
Zacks Investment Research
5 Market-Beating Sector ETFs of Q1 - Zacks Investment Research
Zacks Investment Research
5 Small Biotech ETFs to Watch (Updated 2024) - Investing News Network
Investing News Network
Top Pfizer Shareholders - Investopedia
Investopedia
Top & Flop ETF Areas of Wall Street's Best February in Decade
Zacks Investment Research
The Zacks Analyst Blog Highlights CRPT, CNCR, WISE, AIRR and PKB
Zacks Investment Research
5 Best-Performing Sector ETFs of February
Zacks Investment Research
7 Best Biotech ETFs to Buy Now | Investing | U.S. News - U.S News & World Report Money
U.S News & World Report Money
5 Sector ETFs Beating the Market Halfway Through Q1
Zacks Investment Research
5 Sector ETFs Beating the Market Halfway Through Q1 - Yahoo Finance
Yahoo Finance
Range Debuts 4 Energy-Related ETFs - ETF Trends
ETF Trends
Biotech Stocks, Pharma Heat Up In 2024 As Buyouts, Obesity And AI Drive Excitement - Investor's Business Daily
Investor's Business Daily
Has Biotechnology Bottomed Out? - Master Investor
Master Investor
ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial (NYSE:ADCT) - Seeking Alpha
Seeking Alpha
12 Most Promising Cancer Stocks According to Analysts - Yahoo Finance
Yahoo Finance
4 Cancer Stocks to Consider in 2024 - The Motley Fool
The Motley Fool
IPO News - US IPO Week Ahead: Reinsurer Hamilton Group and biotech CARGO Therapeutics plot next major IPOs ... - Renaissance Capital
Renaissance Capital
This Week in ETFs: 4 New Single-Stock Funds Debut - ETF Trends
ETF Trends
Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2023 - Investing News Network
Investing News Network
14 Best Cancer Stocks To Buy Now - Yahoo Finance
Yahoo Finance
14 Best Cancer Stocks To Buy Now - Yahoo Finance
Yahoo Finance
ASCO Annual Meeting 2023: Precision Oncology Achieving Widespread Adoption - Global X
Global X
Last Week in ETFs: 15 Launches, Closures Continue Rapid Pace - ETF Trends
ETF Trends
Top Healthcare Stocks for June 2023 - Investopedia
Investopedia
Oncology Stocks: 8 Biggest NASDAQ Companies in 2023 - Investing News Network
Investing News Network
Acrivon Therapeutics (ACRV) Stock Price, News & Analysis - MarketBeat
MarketBeat
An Innovative ETF Opportunity That Taps Into Our Increased Understanding of the Human Genome - ETF Trends
ETF Trends
4 Cancer Stocks to Consider in 2024 - The Motley Fool
The Motley Fool
2seventy bio (TSVT) Stock Price, News & Analysis - MarketBeat
MarketBeat
Tyra Biosciences (TYRA) Stock Price, News & Analysis - MarketBeat
MarketBeat
Vor Biopharma (VOR) Stock Price, News & Analysis - MarketBeat
MarketBeat
Cullinan Oncology (CGEM) Stock Price, News & Analysis - MarketBeat
MarketBeat
MorphoSys (MOR) Stock Price, News & Analysis - MarketBeat
MarketBeat
Kymera Therapeutics (KYMR) Stock Price, News & Analysis - MarketBeat
MarketBeat
iTeos Therapeutics (ITOS) Stock Price, News & Analysis - MarketBeat
MarketBeat
Immatics (IMTX) Stock Price, News & Analysis - NASDAQ - MarketBeat
MarketBeat
Precigen (PGEN) Stock Price, News & Analysis - MarketBeat
MarketBeat
Schrödinger (SDGR) Stock Price, News & Analysis - MarketBeat
MarketBeat
SpringWorks Therapeutics (SWTX) Stock Price, News & Analysis - MarketBeat
MarketBeat
IGM Biosciences (IGMS) Stock Price, News & Analysis - MarketBeat
MarketBeat
Genmab A/S (GMAB) Stock Price, News & Analysis - MarketBeat
MarketBeat
BCYC IPO News - Cancer biotech Bicycle Therapeutics prices US IPO at $14, the low end of the range - Renaissance Capital
Renaissance Capital
4 Leading Companies in Genomics - Global X
Global X
Kapitalisierung:
|
Volumen (24h):